

Trials Current as at 10 August 2017

TUMOUR	TRIAL/AGENT: PHASE 1	KEY POINTS	PI	SC
Any	DpC (CMD): Oral Fe chelating agent		BM	LD
Any	Hutchison FGFR antagonist	Paired biopsy	VG	LD
Any	EnGenIC Doxorubin EDV's	No biopsy	VG	LD
Any	BGB-A317 / 290:PD1 inh plus PARP inh	Opening September	BM	PM
SCLC	BGB-A317 / 290:PD1 inh plus PARP inh	Extensive stage	BM	PM
NSCLC	Viralytics: Oncolytic virus + pembrolizumab	, prior I-O ok	VG	PM
RCC	BMS IDO: IDO inhib + Nivolumab	Paired biopsy	BM	CAH
RCC	Corvus: Adenosine antag +/- PDL1 (atezolizumab)	Paired biopsies, prior I-O ok	BM	C-AH
Bladder TCC	BMS IDO: IDO inhib + nivolumab	Paired biopsies, prior I-O ok	BM	C-AH
Bladder TCC	Viralytics: Oncolytic virus + pembrolizumab	Single biopsy, prior I-O ok	VG	PM
Urothelial	BGB-A317 / 290:PD1 inh plus PARP inh		BM	PM
Prostate	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD	BM	PM
Gastric and GOJ	BGB-A317 / 290:PD1 inh plus PARP inh		BM	PM
Gastrooes, HCC	BGBA317: PD1 inhib	No prior I-O, biopsy for gastric cohort	BM	PM
Pancreas	BMS Meso: Anti-mesothelin ADC (+/- nivolumab)	Prospective mesothelin expression IHC	BM	CB
Pancreas	BMS IDO: IDO inhib + nivolumab	Paired biopsies	BM	C-AH
Pancreas	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD		
GIST	GSK BET inhibitor	Paired biopsies	AA	C-AH
Melanoma	BMS IDO: IDO inhib + nivolumab	Paired biopsies, prior I-O ok	BM	C-AH
TNBC	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD	BM	PM
Ovarian	BGB-A317 / 290:PD1 inh plus PARP inh	BRCA mutant (germline or somatic) or HRD; BRCA wildtype	BM	PM

Irina A: 22018 Cheryl-Ann: 22788 Penny M: 22429 Chris B: 22393 Louise D: 22921 Chris P: 22415 Laima M: 22924 Lindsay G: 22419 Shelly F: 22017 Lisa R: 22019 Kim B: 22024

TUMOUR	TRIAL	TRIAL/AGENT: PHASE 2/3	PI	SC
HNSCC- rec/met	BMS study	Open Label, Randomized, Study of Nivolumab + Ipilimumab Vs Extreme Study Regimen as a 1 st line therapy	AM	LM
NSCLC ALK+	ALTA	Open-Label Study of Brigatinib (AP6113) vs Crizotinib	AM	LM
NSCLC	BMS227	Nivolumab or nivolumab + ipilimumab vs platinum doublet	BM	LT
NSCLC	Mirati Lung	PhII MGCD265 in locally advanced or met NSCLC with activating genetic alterations in mesenchymal-epithelial transition factor	AM	LM
NSCLC	BR_31	Double blind placebo adjuvant MEDI4736 in completely resected NSCLC	AM	LM
NSCLC	Fraction lung	A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Subjects with Advanced NSCLC	BM	LT
NSCLC	OSCILLATE	Ph 2 trial of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced NSCLC	AM	LT
Mesothelioma	CA209-743	Nivolumab + Ipilimumab vs Pemetrexed with Cisplatin or Carboplatin as 1st line therapy	AM	LM
mRCC	Javelin Renal	Open label parallel arm study of Avelumab in combination with Axitinib vs Sunitinib monotherapy in first-line	DP	IA
mRCC	Fraction renal	Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced RCC	DP	IA
Bladder TCC	Adjuvant	Open label study of Atezolizumab vs observation as adjuvant therapy in PDL1 selected, high risk after cystectomy	DP	IA
Bladder TCC	Javelin Bladder	Avelumab + supportive care vs best supportive care alone in patients who did not progress after 1st line therapy	DP	IA
Prostate hi risk	Embark	Enzalutamide + leuprolide, enzalutamide monotherapy + placebo in non-metastatic prostate ca progressing after definitive therapy	DP	CP
Prostate	EH prostate biology	Studies of prostate cancer biology	AA	NN
Prostate	OZM-054	Phase II study of cabazitaxel vs abiraterone or enzalutamide in poor prognosis-m castration-resistant prostate cancer	AA	CP
Prostate	ARCHES	Ph III study in castrate sensitive metastatic prostate ca, enzalutamide vs placebo with LHRH agonist	AA	IA
Prostate	PROfound	Ph III study of Olaparib in MCRPC patient with genetic mutation	AA	IA
Prostate	IMbassador	Ph III rand trial of enzalutamide +/- atezo in patients with MCRPC after failure of androgen synthesis inhibitor after taxane	DP	SF
Prostate	IPATential	Ph III rand trial of abi +/- ipatasertib placebo controlled in asymptomatic or mildly symptomatic MCRPC	DP	SF
CRC Stage II	Dynamic	Circulating tumour DNA analysis informing adjuvant chemotherapy	MH	SK
Adj CRC	ASCOLT	Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers	AS	SF
mBRAF mCRC	ARRAY	Open-Label 3-arm study; Encorafenib + Cetuxomab Bimetinib vs Irinotecan/Cetuximab or FOLFIRI/Cetuximab	AS	SF
mCRC	Keynote 177	Pembrolizumab vs chemotherapy in MSI-H or dMMR mCRC	AS	LR
GI NEC	NABNEC	Randomised Ph II: nab-paclitaxel + carboplatin as 1 st line treatment	BM	LR
Adj Gastrooes	Checkmate G/O	Nivolumab or placebo in patients with resected lower esophageal or GOJ	AS	SF
Met Gastrooes	INTEGRATE II	Double-blind Placebo-controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer	AS	LR
Met Gastrooes	MSD Gastric	Pembrolizumab versus Paclitaxel after progression on 1 st line therapy with platinum and fluoropyrimidine	AS	LR
Met Gastrooes	Javelin gastric	Maintenance therapy with Avelumab vs continuation of 1 st line in locally advanced or metastatic	AS	LR
Pancreas	Pancreatic CtDNA	Circulating Tumour DNA as a biomarker	MH	SK
Pancreas	Halo	RDB placebo-contr PEGylated recombinant hyaluronidase (PEGPH20) + nab-Paclitaxel + gemcitabine in hyaluron-high 1 st L	MH	LR
Pancreas	PanCo	Ph III study of Oncosil in untreated metastatic or locally pancreatic ca	MH	KB
Endometrial	Millenium Endometrial	Ph2 MLN0128(dual TORC1/2inhibitor), MLN0128+MLN1117(Pi3Ka Inhibitor), weekly paclitaxel or combination weekly paclitaxel and MLN0128 in advanced, recurrent or persistent EC	GG	KB
Endometrial	PHAEDRA	Ph II trial of Durvalumab in advanced endometrial cancer	GG	KB
Ovarian	DYNAMIC	Circulating Tumour DNA	GG	SK
Breast HER 2+	Penelope B	Palbociclib (CDK) 4/6 inhibitor after neoadjuvant therapy	MW	Fran/LR
Breast HER 2+	Tabitha	Treatment of advanced breast ca in the HER-pos australian patient	MH	
Glioblastoma	Vertu	R Ph II veliparib + RT with adjuvant TMZ + veliparib vs RT+TMZ then TMZ in newly diagnosed GBM with unmethylated (MGMT)	RF	IA
Bone Metastases	TANGO bone pain	Placebo controlled, analgesic subcut Tanezumab (PF-04383119) for cancer pain due to bone mets receiving background opioid	MF	SF
Cough	Methadone Cough	Efficacy of low dose methadone as an antitussive for patients with malignancy	MF	

